
  
    
      
        Background_NNP
        Common_NNP variable_JJ immunodeficiency_NN (_( CVID_NNP )_) and_CC selective_JJ
        immunoglobulin_NN G_NNP subclass_NNS deficiency_NN (_( IgGSD_NNP )_) are_VBP
        characterized_VBN by_IN subnormal_NN serum_NN concentrations_NNS of_IN total_JJ
        IgG_NNP ,_, or_CC by_IN normal_JJ serum_NN total_JJ IgG_NNP concentrations_NNS with_IN
        deficiency_NN of_IN one_CD or_CC more_JJR IgG_NNP subclasses_NNS ,_, respectively_RB ;_: in_IN
        some_DT cases_NNS ,_, IgA_NNP or_CC IgM_NNP levels_NNS are_VBP also_RB subnormal_NN [_NN 1_CD 2_CD 3_CD ]_NN
        ._. Most_JJS persons_NNS are_VBP diagnosed_VBN to_TO have_VB CVID_NNP or_CC IgGSD_NNP because_IN
        they_PRP have_VBP increased_VBN frequency_NN and_CC severity_NN of_IN infections_NNS
        due_JJ to_TO bacteria_NNS and_CC other_JJ microbial_NN pathogens_NNS [_NN 1_CD 4_CD ]_NN ._.
        Although_IN a_DT susceptibility_NN locus_JJ for_IN these_DT disorders_NNS has_VBZ not_RB
        been_VBN identified_VBN ,_, they_PRP often_RB appear_VBP to_TO be_VB familial_NN and_CC to_TO
        segregate_VB with_IN markers_NNS on_IN Ch_NNP 6_CD p_NN [_NN 1_CD 5_CD 6_CD ]_NN ._.
        The_DT purpose_NN of_IN the_DT present_JJ work_NN was_VBD to_TO quantify_VB and_CC
        analyze_VB the_DT frequencies_NNS of_IN HLA-A_NNP and_CC -_: B_NNP phenotypes_NNS and_CC
        haplotypes_NNS in_IN index_NN cases_NNS with_IN CVID_NNP and_CC IgGSD_NNP in_IN central_JJ
        Alabama_NNP who_WP presented_VBD because_IN they_PRP had_VBD increased_VBN frequency_NN
        or_CC severity_NN of_IN infections_NNS ,_, and_CC to_TO compare_VB the_DT present_JJ
        results_NNS to_TO those_DT of_IN control_NN subjects_NNS in_IN this_DT geographic_JJ
        area_NN ._. We_PRP also_RB evaluated_VBD the_DT relationships_NNS of_IN HLA-A_NNP and_CC -_: B_NNP
        phenotype_NN frequencies_NNS and_CC haplotypes_NNS with_IN phenotypes_NNS
        defined_VBN by_IN serum_NN immunoglobulin_NN concentrations_NNS ,_, and_CC we_PRP
        estimated_VBD the_DT combined_VBN frequency_NN of_IN CVID_NNP and_CC IgGSD_NNP in_IN
        central_JJ Alabama_NNP based_VBN upon_IN the_DT occurrence_NN of_IN these_DT
        disorders_NNS in_IN the_DT spouses_NNS of_IN the_DT present_JJ index_NN cases_NNS ._. The_DT
        implications_NNS of_IN the_DT present_JJ results_NNS in_IN determining_VBG the_DT
        hereditary_JJ basis_NN and_CC immunoglobulin_NN phenotype_NN expression_NN of_IN
        CVID_NNP and_CC IgGSD_NNP are_VBP discussed_VBN ._.
      
      
        Methods_NNP
        
          Selection_NN of_IN Subjects_NNP
          
            General_NNP Criteria_NNP for_IN Selection_NN of_IN Study_NNP
            Subjects_NNP
            The_DT performance_NN of_IN this_DT work_NN was_VBD approved_VBN by_IN the_DT
            Institutional_NNP Review_NNP Boards_NNP of_IN Brookwood_NNP Medical_NNP Center_NNP
            and_CC the_DT University_NNP of_IN Alabama_NNP at_IN Birmingham_NNP ,_, and_CC the_DT
            Ethical_NNP Principles_NNPS for_IN Medical_NNP Research_NNP involving_VBG Human_NNP
            Subjects_NNP promulgated_VBD by_IN the_DT World_NNP Medical_NNP Association_NNP
            Declaration_NNP of_IN Helsinki_NNP were_VBD followed_VBN ._. All_DT subjects_NNS
            were_VBD adults_NNS (_( â‰¥_NN 18_CD years_NNS of_IN age_NN )_) who_WP identified_VBD
            themselves_PRP as_IN Caucasians_NNP ;_: each_DT resided_VBN in_IN central_JJ
            Alabama_NNP ._. The_DT first_JJ persons_NNS in_IN respective_JJ families_NNS
            diagnosed_VBN to_TO have_VB CVID_NNP or_CC IgGSD_NNP were_VBD designated_VBN as_IN
            index_NN cases_NNS ._. All_DT index_NN persons_NNS were_VBD diagnosed_VBN in_IN
            routine_JJ medical_JJ care_NN in_IN a_DT single_JJ community_NN medical_JJ
            center_NN ;_: none_NN was_VBD diagnosed_VBN as_IN a_DT consequence_NN of_IN family_NN
            or_CC population_NN screening_NN ._. We_PRP included_VBD all_DT evaluable_JJ
            index_NN patients_NNS diagnosed_VBN between_IN November_NNP 1991_CD and_CC June_NNP
            2002_CD ._.
          
          
            CVID_NNP and_CC IgGSD_NNP Index_NNP Cases_NNS
            Each_DT patient_NN was_VBD diagnosed_VBN to_TO have_VB CVID_NNP or_CC IgGSD_NNP
            deficiency_NN as_IN an_DT adult_NN because_IN he_PRP /_NN she_PRP had_VBD frequent_JJ or_CC
            unusually_RB severe_JJ infections_NNS ._. Each_DT patient_NN had_VBD a_DT single_JJ ,_,
            severe_JJ or_CC life-threatening_JJ infection_NN that_WDT required_VBD
            hospitalization_NN or_CC four_CD or_CC more_JJR infections_NNS per_IN year_NN
            that_WDT required_VBD antibiotic_JJ therapy_NN for_IN at_IN least_JJS two_CD
            consecutive_JJ years_NNS ._. None_NN was_VBD known_VBN to_TO have_VB pre-existing_JJ
            isolated_VBN IgA_NNP deficiency_NN or_CC other_JJ abnormality_NN of_IN
            immunity_NN ._. Diagnoses_NNP were_VBD based_VBN on_IN demonstration_NN of_IN
            persistent_JJ ,_, otherwise_RB unexplained_JJ serum_NN concentrations_NNS
            of_IN immunoglobulins_NNS >_NN 2_CD S_NNP ._. D_NNP ._. below_IN the_DT corresponding_JJ
            mean_NN levels_NNS [_NN 1_CD ]_NN ._. Criteria_NNP for_IN the_DT diagnosis_NN of_IN CVID_NNP
            were_VBD :_: 1_LS )_) decreased_VBD total_JJ serum_NN IgG_NNP concentration_NN ;_: and_CC
            2_LS )_) either_CC decreased_VBD IgG_NNP subclass_NNS (_( es_NNS )_) ,_, decreased_VBD serum_NN
            IgA_NNP concentration_NN ,_, or_CC decreased_VBD serum_NN IgM_NNP concentration_NN
            [_NN 1_CD ]_NN ._. Criteria_NNP for_IN the_DT diagnosis_NN of_IN IgGSD_NNP were_VBD :_: 1_LS )_)
            normal_JJ total_JJ serum_NN IgG_NNP concentration_NN ;_: and_CC 2_LS )_) abnormally_RB
            low_JJ serum_NN concentrations_NNS of_IN one_CD or_CC more_JJR IgG_NNP subclasses_NNS ;_:
            some_DT patients_NNS with_IN IgGSD_NNP also_RB had_VBD decreased_VBN levels_NNS of_IN
            IgA_NNP or_CC IgM_NNP levels_NNS [_NN 1_CD ]_NN ._.
            We_PRP excluded_VBD persons_NNS of_IN African_NNP American_JJ descent_NN
            because_IN :_: 1_LS )_) certain_JJ HLA_NNP types_NNS and_CC haplotypes_NNS differ_VBP
            significantly_RB among_IN Caucasians_NNP and_CC African_NNP Americans_NNPS in_IN
            central_JJ Alabama_NNP [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ;_: 2_LS )_) in_IN adults_NNS ,_, serum_NN
            concentrations_NNS of_IN immunoglobulins_NNS are_VBP often_RB greater_JJR in_IN
            persons_NNS of_IN sub-_NN Saharan_NNP African_JJ descent_NN than_IN in_IN whites_NNS [_NN
            11_CD 12_CD ]_NN ;_: and_CC 3_LS )_) persons_NNS of_IN sub-_NN Saharan_NNP descent_NN occur_VB
            infrequently_RB in_IN series_NN of_IN CVID_NNP or_CC IgGSD_NNP patients_NNS [_NN 4_CD ]_NN
            ,_, and_CC such_JJ patients_NNS are_VBP uncommon_JJ in_IN our_PRP$ experience_NN ._. We_PRP
            also_RB excluded_VBD persons_NNS who_WP had_VBD isolated_VBN deficiencies_NNS of_IN
            IgA_NNP or_CC IgM_NNP ,_, those_DT with_IN hypogammaglobulinemia_NN
            attributable_JJ to_TO B-_NNP cell_NN neoplasms_NNS (_( 
            e_SYM ._. g_SYM ._. ,_, B-_NNP chronic_JJ lymphocytic_JJ
            leukemia_NN ,_, plasma_NN cell_NN myeloma_NN ,_, macroglobulinemia_NN ,_, or_CC
            non-_NN Hodgkin_NNP 's_POS lymphoma_NN )_) or_CC those_DT with_IN markedly_RB
            increased_VBN immunoglobulin_NN loss_NN (_( 
            e_SYM ._. g_SYM ._. ,_, nephrotic_JJ syndrome_NN or_CC
            protein-losing_JJ enteropathy_NN )_) ._.
          
          
            Control_NNP Subjects_NNP
            Data_NNS from_IN 1_CD ,_, 321_CD apparently_RB normal_JJ ,_, unrelated_JJ
            Caucasian_NNP adult_NN subjects_NNS from_IN Alabama_NNP who_WP had_VBD undergone_VBN
            HLA-A_NNP and_CC -_: B_NNP phenotype_NN analysis_NN as_IN part_NN of_IN paternity_NN
            testing_NN were_VBD used_VBN to_TO estimate_VB allele_NN and_CC gene_NN
            frequencies_NNS [_NN 10_CD 13_CD ]_NN ._. HLA-A_NNP and_CC -_: B_NNP haplotypes_NNS were_VBD
            determined_VBN in_IN 751_CD unrelated_JJ Caucasian_NNP subjects_NNS from_IN
            Alabama_NNP who_WP had_VBD undergone_VBN testing_NN to_TO establish_VB
            paternity_NN [_NN 10_CD ]_NN ._. Haplotypes_NNP were_VBD assessed_VBN from_IN a_DT
            child_NN and_CC his_PRP$ /_NN her_PRP$ mother_NN or_CC father_NN ,_, and_CC included_VBN in_IN the_DT
            data_NNS set_VBN ._. Preliminary_JJ data_NNS analysis_NN revealed_VBD that_IN
            frequencies_NNS of_IN the_DT major_JJ HLA-A_NNP and_CC -_: B_NNP haplotypes_NNS
            observed_VBD in_IN the_DT present_JJ control_NN subjects_NNS were_VBD similar_JJ
            to_TO those_DT estimated_VBN to_TO occur_VB in_IN Caucasians_NNP from_IN a_DT large_JJ
            national_JJ bone_NN marrow_NN donor_NN program_NN [_NN 14_CD ]_NN ._.
          
          
            Family_NN Members_NNPS
            We_PRP diagnosed_VBD CVID_NNP or_CC IgGSD_NNP deficiency_NN in_IN some_DT family_NN
            members_NNS using_VBG the_DT same_JJ criteria_NNS defined_VBD herein_NN for_IN
            index_NN patients_NNS ._. These_DT persons_NNS presented_VBD themselves_PRP for_IN
            evaluation_NN after_IN an_DT index_NN case_NN was_VBD diagnosed_VBN in_IN their_PRP$
            respective_JJ kinships_NNS because_IN they_PRP also_RB had_VBD increased_VBN
            frequency_NN and_CC severity_NN of_IN bacterial_JJ infections_NNS ._.
            Although_IN other_JJ relatives_NNS of_IN index_NN cases_NNS were_VBD also_RB
            reported_VBN to_TO have_VB increased_VBN frequency_NN and_CC severity_NN of_IN
            infections_NNS or_CC to_TO have_VB some_DT form_NN of_IN antibody_NN deficiency_NN ,_,
            they_PRP were_VBD not_RB included_VBN in_IN the_DT present_JJ study_NN because_IN we_PRP
            did_VBD not_RB evaluate_VB them_PRP ._. Screening_NNP or_CC other_JJ systematic_JJ
            testing_NN of_IN family_NN members_NNS of_IN the_DT present_JJ index_NN cases_NNS
            was_VBD beyond_IN the_DT scope_NN of_IN the_DT present_JJ study_NN ._.
          
        
        
          Laboratory_NNP Methods_NNP
          Serum_NNP concentrations_NNS of_IN IgG_NNP ,_, IgA_NNP ,_, IgM_NNP ,_, and_CC IgG_NNP
          subclasses_NNS were_VBD measured_VBN using_VBG standard_JJ automated_VBN methods_NNS
          before_IN IgG_NNP replacement_NN therapy_NN was_VBD initiated_VBN ._. Reference_NNP
          ranges_NNS for_IN serum_NN immunoglobulin_NN concentrations_NNS are_VBP :_: total_JJ
          IgG_NNP 700_CD -_: 1600_CD mg_NN /_NN dL_NN ;_: IgG_NNP 
          1_CD 422_CD -_: 1292_CD mg_NN /_NN dL_NN ;_: IgG_NNP 
          2_CD 117_CD -_: 747_CD mg_NN /_NN dL_NN ;_: IgG_NNP 
          3_CD 41_CD -_: 129_CD mg_NN /_NN dL_NN ;_: IgG_NNP 
          4_CD 1_CD -_: 291_CD mg_NN /_NN dL_NN ;_: total_JJ IgA_NNP 70_CD -_: 400_CD
          mg_NN /_NN dL_NN ;_: and_CC IgM_NNP 40_CD -_: 230_CD mg_NN /_NN dL_NN ._. The_DT basis_NN of_IN these_DT
          reference_NN ranges_NNS has_VBZ been_VBN reported_VBN elsewhere_RB [_NN 15_CD ]_NN ._.
          Deficiency_NNP of_IN an_DT immunoglobulin_NN class_NN or_CC subclass_NNS was_VBD
          defined_VBN by_IN a_DT serum_NN concentration_NN at_IN diagnosis_NN that_WDT was_VBD
          less_JJR than_IN the_DT corresponding_JJ lower_JJR reference_NN limit_NN ._.
          Measurement_NNP of_IN IgA_NNP subclasses_NNS ,_, IgD_NNP ,_, or_CC IgE_NNP in_IN serum_NN was_VBD
          not_RB routinely_RB performed_VBN ._.
          HLA_NNP -_: A_DT and_CC -_: B_NNP alleles_NNS were_VBD detected_VBN using_VBG
          low-resolution_JJ DNA-based_NNP typing_VBG (_( PCR_NNP /_NN sequence-specific_JJ
          oligonucleotide_NN probe_NN )_) in_IN index_NN cases_NNS [_NN 16_CD ]_NN ._. Control_NNP
          subjects_NNS were_VBD tested_VBN using_VBG the_DT microdroplet_NN
          lymphocytotoxicity_NN test_NN [_NN 8_CD ]_NN ;_: subjects_NNS were_VBD evaluated_VBN
          using_VBG antisera_NN that_WDT detected_VBD allele_NN assignments_NNS described_VBD
          in_IN the_DT 9_CD thInternational_NN Histocompatibility_NNP Workshop_NNP [_NN 17_CD
          ]_NN ._. Because_IN the_DT levels_NNS of_IN resolution_NN of_IN the_DT DNA-based_NNP and_CC
          serological_JJ typing_VBG methods_NNS we_PRP used_VBD are_VBP similar_JJ ,_, alleles_NNS
          detected_VBN by_IN these_DT respective_JJ methods_NNS provide_VBP concordant_NN
          allele_NN assignments_NNS ,_, with_IN the_DT exception_NN of_IN B_NNP *_NN 70_CD and_CC B_NNP *_NN 71_CD
          that_WDT were_VBD not_RB detected_VBN by_IN serological_JJ methods_NNS ._. HLA_NNP typing_VBG
          of_IN family_NN members_NNS was_VBD performed_VBN to_TO permit_VB assignment_NN of_IN
          Ch_NNP 6_CD p_NN haplotypes_NNS ._. In_IN each_DT index_NN patient_NN in_IN whom_WP a_DT single_VB A_DT
          or_CC B_NNP allele_NN was_VBD detected_VBN by_IN DNA-based_NNP typing_VBG ,_, we_PRP verified_VBN
          the_DT allele_NN (_( s_VBZ )_) and_CC set_VBN phase_NN to_TO ascertain_VB haplotypes_NNS of_IN
          the_DT index_NN patient_NN using_VBG HLA_NNP analyses_NNS of_IN appropriate_JJ
          family_NN members_NNS ._. For_IN the_DT present_JJ analysis_NN ,_, all_DT haplotypes_NNS
          were_VBD defined_VBN only_RB by_IN A_DT and_CC B_NNP alleles_NNS ._.
        
        
          Statistical_NNP Considerations_NNP
          A_DT data_NNS set_VBN that_WDT included_VBD HLA-A_NNP and_CC -_: B_NNP phenotypes_NNS in_IN
          240_CD index_NN patients_NNS with_IN either_DT CVID_NNP or_CC IgGSD_NNP and_CC HLA-A_NNP
          and_CC -_: B_NNP haplotypes_NNS in_IN 195_CD of_IN these_DT 240_CD index_NN patients_NNS was_VBD
          available_JJ ._. Absolute_JJ or_CC "_'' uncorrected_JJ "_'' values_NNS of_IN A_DT and_CC B_NNP
          phenotype_NN frequencies_NNS in_IN index_NN cases_NNS ,_, A_DT and_CC B_NNP haplotype_NN
          frequencies_NNS ,_, and_CC occurrence_NN of_IN two-haplotype_JJ combinations_NNS
          were_VBD calculated_VBN after_IN enumeration_NN of_IN the_DT raw_JJ data_NN ._. To_TO
          correct_VB for_IN the_DT possible_JJ occurrence_NN of_IN spurious_JJ HLA_NNP
          antigen_NN and_CC haplotype_NN associations_NNS due_JJ to_TO multiple_JJ
          comparisons_NNS ,_, we_PRP also_RB computed_JJ values_NNS of_IN 
          p_NN using_VBG the_DT Bonferroni_NNP inequality_NN
          method_NN [_NN 18_CD ]_NN ._. "_'' Corrected_NNP "_'' values_NNS of_IN 
          p_NN are_VBP displayed_VBN in_IN tabular_NN form_NN
          along_IN with_IN "_'' uncorrected_JJ "_'' values_NNS ._. A_DT computer_NN spreadsheet_NN
          (_( Excel_NNP 2000_CD ,_, Microsoft_NNP Corp_NNP ._. ,_, Redmond_NNP ,_, WA_NNP )_) and_CC a_DT
          statistical_JJ program_NN (_( GB-Stat_NNP ,_, v_NN ._. 8_CD ._. 0_CD 2000_CD ,_, Dynamic_NNP
          Microsystems_NNPS ,_, Inc_NNP ._. ,_, Silver_NNP Spring_NNP ,_, MD_NNP )_) were_VBD used_VBN to_TO
          perform_VB the_DT present_JJ analyses_NNS ._. Means_NNP were_VBD compared_VBN using_VBG a_DT
          student_NN t-test_JJ (_( two-tail_JJ )_) ._. Frequency_NNP values_NNS were_VBD compared_VBN
          using_VBG chi-square_JJ analysis_NN or_CC Fisher_NNP 's_POS exact_JJ test_NN
          (_( one-tail_JJ )_) ,_, as_IN appropriate_JJ ._. A_DT value_NN of_IN 
          p_NN <_NN 0_CD ._. 05_CD was_VBD defined_VBN as_IN
          significant_JJ ._. Only_RB significant_JJ values_NNS of_IN 
          p_NN are_VBP displayed_VBN ,_, and_CC these_DT are_VBP
          expressed_VBN to_TO four_CD significant_JJ figures_NNS ._.
        
      
      
        Results_NNS
        
          General_NNP Characteristics_NNP of_IN CVID_NNP and_CC IgGSD_NNP Index_NNP
          Patients_NNPS
          There_EX were_VBD approximately_RB equal_JJ fractions_NNS of_IN index_NN
          patients_NNS with_IN CVID_NNP and_CC IgGSD_NNP ,_, respectively_RB (_( Table_NNP 1_LS )_) ._.
          There_EX was_VBD a_DT preponderance_NN of_IN women_NNS in_IN index_NN patients_NNS in_IN
          both_DT disorders_NNS ._. The_DT mean_NN ages_NNS of_IN patients_NNS in_IN CVID_NNP and_CC
          IgGSD_NNP groups_NNS were_VBD similar_JJ ._. In_IN CVID_NNP ,_, the_DT most_RBS frequent_JJ
          pattern_NN of_IN IgG_NNP deficiency_NN was_VBD that_IN of_IN IgG_NNP 
          1_CD +_NN IgG_NNP 
          3_CD subclasses_NNS ._. In_IN persons_NNS with_IN IgGSD_NNP ,_,
          isolated_VBD IgG_NNP 
          3_CD deficiency_NN was_VBD the_DT most_RBS frequent_JJ IgG_NNP
          subclass_NNS deficiency_NN phenotype_NN (_( Table_NNP 1_LS )_) ._. Eight_CD of_IN the_DT
          present_JJ index_NN patients_NNS (_( 3_CD CVID_NNP ,_, 5_CD IgGSD_NNP ;_: 2_CD men_NNS ,_, 6_CD women_NNS )_)
          also_RB had_VBD hemochromatosis_NNS associated_VBN with_IN homozygosity_NN for_IN
          
          HFE_NNP C_NNP 282_CD Y_NNP on_IN Ch_NNP 6_CD p_NN ;_: another_DT man_NN had_VBD
          CVID_NNP and_CC a_DT hemochromatosis_NNS phenotype_NN associated_VBN with_IN the_DT 
          HFE_NNP genotype_NN C_NNP 282_CD Y_NNP /_NN H_NNP 63_CD D_NNP ._.
        
        
          Frequencies_NNP of_IN HLA-A_NNP and_CC -_: B_NNP Phenotypes_NNP
          Sixteen_NNP A_DT phenotypes_NNS were_VBD detected_VBN in_IN 240_CD index_NN cases_NNS
          and_CC control_NN subjects_NNS (_( Table_NNP 2_LS )_) ._. The_DT most_RBS frequent_JJ A_DT
          phenotypes_NNS in_IN index_NN cases_NNS were_VBD A_DT *_NN 02_CD (_( 0_CD ._. 5292_CD )_) ,_, A_DT *_NN 01_CD
          (_( 0_CD ._. 3458_CD )_) ,_, and_CC A_DT *_NN 03_CD (_( 0_CD ._. 2875_CD )_) ._. The_DT most_RBS frequent_JJ A_DT
          phenotypes_NNS in_IN controls_NNS were_VBD A_DT *_NN 02_CD (_( 0_CD ._. 5206_CD )_) ,_, A_DT *_NN 01_CD (_( 0_CD ._. 3397_CD )_) ,_,
          and_CC A_DT *_NN 03_CD (_( 0_CD ._. 2739_CD )_) ._. The_DT phenotype_NN A_DT *_NN 24_CD occurred_VBD with_IN
          significantly_RB greater_JJR frequency_NN in_IN index_NN cases_NNS (_( 0_CD ._. 3000_CD
          index_NN cases_VBZ vs_NNS ._. 0_CD ._. 1304_CD controls_NNS ;_: 
          p_NN <_NN 0_CD ._. 0001_CD "_'' uncorrected_JJ "_'' and_CC 
          p_NN <_NN 0_CD ._. 0016_CD "_'' corrected_VBN "_'' )_) ._. There_EX
          were_VBD no_DT other_JJ significant_JJ differences_NNS in_IN HLA-A_NNP phenotype_NN
          frequencies_NNS between_IN these_DT groups_NNS (_( Table_NNP 2_LS )_) ._.
          Thirty-two_NNP B_NNP phenotypes_NNS were_VBD detected_VBN in_IN 240_CD index_NN
          cases_NNS (_( Table_NNP 3_LS )_) ._. Thirty_NNP B_NNP phenotypes_NNS were_VBD detected_VBN in_IN
          control_NN subjects_NNS ._. The_DT most_RBS frequent_JJ B_NNP phenotypes_NNS in_IN index_NN
          cases_NNS were_VBD B_NNP *_NN 44_CD (_( 0_CD ._. 3167_CD )_) ,_, B_NNP *_NN 07_CD (_( 0_CD ._. 2667_CD )_) ,_, and_CC B_NNP *_NN 08_CD
          (_( 0_CD ._. 2583_CD )_) ._. The_DT most_RBS frequent_JJ B_NNP alleles_NNS in_IN controls_NNS were_VBD
          B_NNP *_NN 44_CD (_( 0_CD ._. 2866_CD )_) ,_, B_NNP *_NN 08_CD (_( 0_CD ._. 2487_CD )_) ,_, and_CC B_NNP *_NN 07_CD (_( 0_CD ._. 2259_CD )_) ._. The_DT
          frequencies_NNS of_IN B_NNP *_NN 14_CD ,_, B_NNP *_NN 15_CD ,_, B_NNP *_NN 35_CD ,_, B_NNP *_NN 40_CD ,_, B_NNP *_NN 49_CD ,_, and_CC B_NNP *_NN 50_CD
          were_VBD significantly_RB greater_JJR in_IN index_NN cases_NNS based_VBN on_IN
          "_'' uncorrected_JJ "_'' values_NNS of_IN 
          p_NN (_( Table_NNP 3_LS )_) ._. The_DT frequencies_NNS of_IN
          B_NNP *_NN 14_CD and_CC B_NNP *_NN 40_CD were_VBD significantly_RB greater_JJR in_IN index_NN cases_NNS
          based_VBN on_IN "_'' corrected_VBN "_'' values_NNS of_IN 
          p_NN (_( Table_NNP 3_LS )_) ._. The_DT frequencies_NNS of_IN
          B_NNP *_NN 58_CD and_CC B_NNP *_NN 62_CD were_VBD significantly_RB lower_JJR in_IN index_NN cases_NNS
          based_VBN on_IN "_'' uncorrected_JJ "_'' values_NNS of_IN 
          p_NN (_( Table_NNP 3_LS )_) ._. The_DT frequency_NN of_IN B_NNP *_NN 62_CD
          was_VBD significantly_RB lower_JJR in_IN index_NN cases_NNS based_VBN on_IN a_DT
          "_'' corrected_VBN "_'' value_NN of_IN 
          p_NN (_( Table_NNP 3_LS )_) ._.
        
        
          Frequencies_NNP of_IN HLA-A_NNP and_CC -_: B_NNP Haplotypes_NNP
          Data_NNP were_VBD available_JJ that_WDT permitted_VBD frequency_NN
          comparisons_NNS to_TO be_VB made_VBN between_IN index_NN cases_NNS and_CC probands_NNS
          for_IN 85_CD haplotypes_NNS ._. The_DT most_RBS frequent_JJ haplotypes_NNS in_IN index_NN
          cases_NNS were_VBD A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD (_( frequency_NN 0_CD ._. 1385_CD )_) ,_, A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD
          (_( frequency_NN 0_CD ._. 1308_CD )_) ,_, and_CC A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD (_( frequency_NN 0_CD ._. 1000_CD )_)
          (_( Table_NNP 4_LS )_) ._. Each_DT of_IN these_DT haplotypes_NNS was_VBD significantly_RB
          more_RBR frequent_JJ in_IN index_NN cases_NNS than_IN in_IN control_NN subjects_NNS
          (_( "_'' uncorrected_JJ "_'' values_NNS of_IN 
          p_NN <_NN 0_CD ._. 0001_CD ,_, 0_CD ._. 0252_CD ,_, and_CC 0_CD ._. 0011_CD ,_,
          respectively_RB )_) (_( Table_NNP 4_LS )_) ._. After_IN performing_VBG the_DT Bonferroni_NNP
          corrections_NNS ,_, the_DT frequency_NN of_IN A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD alone_RB was_VBD
          significantly_RB increased_VBN in_IN probands_NNS (_( 
          p_NN <_NN 0_CD ._. 0085_CD )_) (_( Table_NNP 4_LS )_) ._. Three_CD
          other_JJ haplotypes_NNS were_VBD also_RB significantly_RB more_RBR frequent_JJ in_IN
          index_NN cases_NNS based_VBN on_IN "_'' uncorrected_JJ "_'' values_NNS of_IN 
          p_NN ._. These_DT were_VBD A_DT *_NN 03_CD -_: B_NNP *_NN 14_CD ,_,
          A_DT *_NN 31_CD -_: B_NNP *_NN 40_CD ,_, and_CC A_DT *_NN 32_CD -_: B_NNP *_NN 14_CD (_( Table_NNP 4_LS )_) ._. The_DT combined_VBN
          frequencies_NNS of_IN these_DT three_CD latter_JJ haplotypes_NNS were_VBD 0_CD ._. 0411_CD
          in_IN index_NN patients_NNS and_CC 0_CD ._. 0126_CD in_IN control_NN subjects_NNS (_( 
          p_NN <_NN 0_CD ._. 0002_CD "_'' uncorrected_JJ "_'' and_CC 
          p_NN =_SYM 0_CD ._. 0166_CD "_'' corrected_VBN "_'' )_) ._. Two_CD
          haplotypes_NNS were_VBD significantly_RB more_RBR frequent_JJ in_IN control_NN
          subjects_NNS based_VBN on_IN "_'' uncorrected_JJ "_'' values_NNS of_IN 
          p_NN ._. These_DT were_VBD A_DT *_NN 02_CD -_: B_NNP *_NN 60_CD and_CC
          A_DT *_NN 03_CD -_: B_NNP *_NN 44_CD (_( Table_NNP 4_LS )_) ._. However_RB ,_, these_DT differences_NNS were_VBD no_DT
          longer_RB significant_JJ after_IN correction_NN using_VBG the_DT Bonferroni_NNP
          method_NN ._. Homozygosity_NNP for_IN these_DT haplotypes_NNS was_VBD observed_VBN in_IN
          some_DT index_NN cases_NNS :_: A_DT *_NN 02_CD -_: B_NNP *_NN 07_CD (_( n_NN =_SYM 1_LS )_) ;_: A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD (_( n_NN =_SYM 4_LS )_) ;_:
          A_DT *_NN 02_CD -_: B_NNP *_NN 62_CD (_( n_NN =_SYM 1_LS )_) ;_: and_CC A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD (_( n_NN =_SYM 2_LS )_) ._.
          Fifty-two_JJ of_IN 195_CD index_NN patients_NNS (_( 26_CD ._. 7_CD %_NN )_) were_VBD
          HLA-haploidentical_NNP with_IN at_IN least_JJS one_CD other_JJ index_NN case_NN in_IN
          the_DT present_JJ study_NN (_( Table_NNP 5_LS )_) ._. Forty-eight_NNP of_IN these_DT 52_CD
          index_NN patients_NNS (_( 92_CD ._. 3_LS %_NN )_) had_VBD the_DT haplotypes_NNS A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD ,_,
          A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD ,_, or_CC A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD ._. Altogether_RB ,_, eighteen_NN different_JJ
          haplotypes_NNS defined_VBN by_IN A_DT and_CC B_NNP typing_VBG were_VBD observed_VBN in_IN
          these_DT 52_CD index_NN cases_NNS (_( Table_NNP 5_LS )_) ._.
        
        
          Segregation_NNP of_IN HLA_NNP Haplotypes_NNP with_IN CVID_NNP or_CC IgGSD_NNP in_IN
          Kinships_NNP
          We_PRP diagnosed_VBD CVID_NNP or_CC IgGSD_NNP in_IN first-degree_JJ or_CC other_JJ
          relatives_NNS of_IN 26_CD of_IN 195_CD index_NN patients_NNS for_IN whom_WP HLA-A_NNP and_CC
          -_: B_NNP haplotypes_NNS had_VBD been_VBN ascertained_JJ ._. These_DT haplotypes_NNS
          segregated_VBD with_IN CVID_NNP or_CC IgGSD_NNP in_IN 24_CD of_IN the_DT 26_CD kinships_NNS :_:
          A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD (_( 10_CD kinships_NNS )_) ;_: A_DT *_NN 02_CD -_: B_NNP *_NN 08_CD (_( 1_CD kinship_NN )_) ;_: A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD
          (_( 8_CD kinships_NNS )_) (_( Fig_NNP ._. 1_LS )_) ;_: A_DT *_NN 02_CD -_: B_NNP *_NN 50_CD (_( 1_CD kinship_NN )_) ;_: A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD
          (_( 1_CD kinship_NN )_) ;_: A_DT *_NN 11_CD -_: B_NNP *_NN 35_CD (_( 1_CD kinship_NN )_) ;_: and_CC A_DT *_NN 29_CD -_: B_NNP *_NN 44_CD (_( 2_CD
          kinships_NNS )_) ._. In_IN one_CD of_IN the_DT two_CD remaining_VBG kinships_NNS ,_, both_DT
          A_DT *_NN 02_CD -_: B_NNP *_NN 07_CD and_CC A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD segregated_VBD with_IN CVID_NNP or_CC IgGSD_NNP
          (_( Fig_NNP 2_CD ._. )_) ._. In_IN the_DT other_JJ remaining_VBG kinship_NN ,_, one_CD index_NN
          patient_NN and_CC her_PRP$ sister_NN had_VBD IgGSD_NNP but_CC they_PRP were_VBD
          HLA-nonidentical_NNP ._. However_RB ,_, each_DT of_IN these_DT women_NNS inherited_VBD
          a_DT haplotype_NN significantly_RB associated_VBN with_IN CVID_NNP and_CC IgGSD_NNP
          (_( index_NN patient_NN A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD and_CC A_DT *_NN 03_CD -_: B_NNP *_NN 57_CD ;_: sister_NN A_DT *_NN 03_CD -_: B_NNP *_NN 35_CD
          and_CC A_DT *_NN 23_CD -_: B_NNP *_NN 27_CD )_) ._.
        
        
          Relationships_NNPS of_IN HLA_NNP Phenotypes_NNP and_CC Haplotypes_NNP to_TO
          Immunoglobulin_NNP Phenotypes_NNP
          
            Comparison_NNP of_IN HLA-A_NNP and_CC -_: B_NNP Phenotype_NNP Frequencies_NNP
            in_IN CVID_NNP and_CC IgGSD_NNP
            The_DT frequencies_NNS of_IN A_DT phenotypes_NNS were_VBD similar_JJ in_IN the_DT
            CVID_NNP and_CC IgGSD_NNP ,_, with_IN the_DT exceptions_NNS that_IN HLA-A_NNP *_NN 24_CD which_WDT
            occurred_VBD with_IN significantly_RB greater_JJR frequency_NN in_IN IgGSD_NNP
            cases_NNS (_( 0_CD ._. 4206_CD vs_NNS ._. 0_CD ._. 1667_CD CVID_NNP ,_, 
            p_NN =_SYM <_NN 0_CD ._. 0001_CD )_) ,_, and_CC that_IN
            HLA-A_NNP *_NN 31_CD was_VBD more_RBR frequent_JJ in_IN CVID_NNP cases_NNS (_( 0_CD ._. 0877_CD vs_NNS ._.
            0_CD ._. 0238_CD IgGSD_NNP ,_, 
            p_NN =_SYM 0_CD ._. 0277_CD )_) ._. The_DT frequencies_NNS of_IN
            HLA-B_NNP phenotypes_NNS were_VBD similar_JJ in_IN the_DT two_CD groups_NNS ,_, with_IN
            the_DT exceptions_NNS that_IN B_NNP *_NN 07_CD and_CC B_NNP *_NN 50_CD occurred_VBD with_IN
            significantly_RB greater_JJR frequencies_NNS in_IN IgGSD_NNP cases_NNS
            (_( 0_CD ._. 3333_CD vs_NNS ._. 0_CD ._. 1930_CD CVID_NNP ,_, 
            p_NN =_SYM 0_CD ._. 0101_CD ;_: and_CC 0_CD ._. 0635_CD vs_NNS ._. 0_CD ,_, 
            p_NN =_SYM 0_CD ._. 0052_CD ,_, respectively_RB )_) ,_, and_CC
            that_IN B_NNP *_NN 55_CD occurred_VBD more_RBR frequently_RB in_IN CVID_NNP cases_NNS
            (_( 0_CD ._. 0439_CD vs_NNS ._. 0_CD IgGSD_NNP ,_, 
            p_NN =_SYM 0_CD ._. 0231_CD )_) ._.
          
          
            Comparison_NNP of_IN Haplotype_NNP Frequencies_NNP in_IN CVID_NNP and_CC
            IgGSD_NNP
            The_DT haplotype_NN frequencies_NNS in_IN CVID_NNP and_CC IgGSD_NNP did_VBD not_RB
            differ_VB significantly_RB ,_, with_IN two_CD exceptions_NNS ._. The_DT
            frequency_NN of_IN A_DT *_NN 23_CD -_: B_NNP *_NN 44_CD was_VBD significantly_RB greater_JJR in_IN
            CVID_NNP patients_NNS than_IN in_IN IgGSD_NNP patients_NNS (_( 0_CD ._. 0263_CD vs_NNS ._. 0_CD ,_,
            respectively_RB ,_, 
            p_NN =_SYM 0_CD ._. 0267_CD )_) ._. The_DT frequency_NN of_IN
            A_DT *_NN 24_CD -_: B_NNP *_NN 35_CD was_VBD greater_JJR in_IN patients_NNS with_IN IgGSD_NNP than_IN in_IN
            patients_NNS with_IN CVID_NNP (_( 0_CD ._. 0250_CD vs_NNS ._. 0_CD ,_, respectively_RB ,_, 
            p_NN =_SYM 0_CD ._. 0346_CD )_) ._.
          
          
            Possible_JJ Dose_NNP Effect_NN of_IN Haplotype_NNP on_IN Total_NNP Serum_NNP
            Immunoglobulin_NNP Concentrations_NNP
            Eleven_CD haplotypes_NNS occurred_VBD with_IN significantly_RB
            greater_JJR frequency_NN in_IN index_NN patients_NNS with_IN CVID_NNP and_CC IgGSD_NNP
            than_IN in_IN control_NN subjects_NNS (_( described_VBD above_IN )_) ._. Mean_VB values_NNS
            of_IN serum_NN IgG_NNP ,_, IgA_NNP ,_, or_CC IgM_NNP did_VBD not_RB vary_VB significantly_RB
            according_VBG to_TO the_DT inheritance_NN of_IN 0_CD ,_, 1_CD ,_, or_CC 2_CD of_IN these_DT
            eleven_CD haplotypes_NNS (_( Table_NNP 6_CD )_) ._. Similarly_RB ,_, some_DT index_NN
            patients_NNS in_IN each_DT pattern_NN of_IN IgG_NNP subclass_NNS deficiency_NN
            were_VBD positive_JJ for_IN one_CD or_CC two_CD of_IN these_DT eleven_CD
            haplotypes_NNS ,_, with_IN the_DT exception_NN of_IN the_DT sole_JJ index_NN
            patient_NN with_IN deficiencies_NNS of_IN IgG_NNP 
            1_CD ,_, IgG_NNP 
            2_CD ,_, and_CC IgG_NNP 
            4_CD who_WP did_VBD not_RB have_VB any_DT of_IN these_DT
            twelve_CD haplotypes_NNS ._.
          
          
            Frequencies_NNP of_IN Index_NNP Patients_NNPS with_IN HLA_NNP Haplotype_NNP
            A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD
            Some_DT reports_NNS suggest_VBP that_IN IgA_NNP deficiency_NN segregates_NNS
            with_IN a_DT HLA_NNP haplotype_NN (_( s_VBZ )_) containing_VBG A_DT *_NN 01_CD ,_, B_NNP *_NN 08_CD in_IN some_DT
            families_NNS [_NN 4_CD 5_CD 6_CD 19_CD 20_CD ]_NN ._. Thus_RB ,_, we_PRP analyzed_VBD the_DT
            frequencies_NNS of_IN the_DT haplotype_NN A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD in_IN the_DT present_JJ
            index_NN patients_NNS grouped_VBN according_VBG to_TO presence_NN of_IN normal_JJ
            or_CC subnormal_NN pre-treatment_JJ serum_NN concentrations_NNS of_IN IgG_NNP ,_,
            IgA_NNP ,_, and_CC IgM_NNP ,_, respectively_RB ._. Although_IN frequencies_NNS of_IN
            positivity_NN for_IN A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD were_VBD slightly_RB greater_JJR in_IN index_NN
            patients_NNS who_WP had_VBD deficiencies_NNS of_IN IgG_NNP ,_, IgA_NNP ,_, or_CC IgM_NNP ,_,
            these_DT differences_NNS were_VBD not_RB significant_JJ (_( Table_NNP 7_CD )_) ._. There_EX
            were_VBD insufficient_JJ numbers_NNS of_IN index_NN patients_NNS homozygous_JJ
            for_IN A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD to_TO estimate_VB the_DT effect_NN of_IN homozygosity_NN
            for_IN this_DT haplotype_NN on_IN serum_NN immunoglobulin_NN
            concentrations_NNS ._.
          
          
            Disparity_NNP of_IN Immunoglobulin_NNP Phenotype_NNP in_IN Family_NNP
            Members_NNPS with_IN Same_JJ HLA_NNP Haplotype_NNP
            In_IN some_DT kinships_NNS ,_, different_JJ immunoglobulin_NN
            deficiency_NN phenotypes_NNS were_VBD observed_VBN among_IN family_NN
            members_NNS with_IN CVID_NNP or_CC IgGSD_NNP who_WP shared_VBD HLA-A_NNP and_CC -_: B_NNP
            haplotypes_NNS ._. One_CD representative_NN pedigree_NN demonstrating_VBG
            these_DT disparities_NNS between_IN immunoglobulin_NN phenotype_NN ,_,
            frequency_NN of_IN infections_NNS ,_, and_CC HLA_NNP haplotype_NN is_VBZ displayed_VBN
            in_IN Figure_NN 1_CD ._. In_IN a_DT second_JJ kinship_NN ,_, two_CD different_JJ
            haplotypes_NNS segregated_VBD with_IN antibody_NN deficiency_NN ,_,
            although_IN the_DT immunoglobulin_NN deficiency_NN pattern_NN was_VBD
            different_JJ in_IN each_DT of_IN three_CD affected_VBN family_NN members_NNS
            (_( Fig_NNP ._. 2_LS )_) ._. One_CD pair_NN of_IN monozygotic_JJ twins_NNS was_VBD available_JJ
            for_IN evaluation_NN ._. The_DT index_NN patient_NN had_VBD IgGSD_NNP (_( IgG_NNP 
            3_CD subclass_NNS deficiency_NN ;_: HLA-A_NNP 24_CD ,_, 25_CD ;_: -_:
            B_NNP 15_CD ,_, 49_CD )_) and_CC recurrent_JJ upper_JJ and_CC lower_JJR respiratory_JJ
            tract_NN infections_NNS ._. Her_PRP$ twin_JJ had_VBD normal_JJ serum_NN
            concentrations_NNS of_IN total_JJ IgG_NNP ,_, IgG_NNP subclasses_NNS ,_, IgA_NNP ,_, and_CC
            IgM_NNP ,_, and_CC did_VBD not_RB report_VB increased_VBD frequency_NN or_CC severity_NN
            of_IN infections_NNS ._.
          
        
        
          Estimation_NNP of_IN Population_NNP Frequency_NNP of_IN CVID_NNP and_CC
          IgGSD_NNP
          The_DT occurrence_NN of_IN CVID_NNP and_CC IgGSD_NNP in_IN spouses_NNS of_IN the_DT
          present_JJ index_NN cases_NNS permitted_VBD us_PRP to_TO estimate_VB the_DT combined_VBN
          population_NN frequency_NN of_IN CVID_NNP and_CC IgGSD_NNP in_IN adults_NNS ._. At_IN the_DT
          time_NN of_IN diagnosis_NN ,_, 217_CD of_IN the_DT present_JJ 240_CD index_NN cases_NNS had_VBD
          spouses_NNS ._. Of_IN these_DT 217_CD spouses_NNS ,_, we_PRP diagnosed_VBD CVID_NNP in_IN one_CD
          and_CC IgGSD_NNP in_IN another_DT because_IN they_PRP also_RB had_VBD increased_VBN
          frequency_NN and_CC severity_NN of_IN bacterial_JJ infections_NNS ,_,
          predominantly_RB those_DT of_IN the_DT upper_JJ and_CC lower_JJR respiratory_JJ
          tracts_NNS ._. Thus_RB ,_, a_DT conservative_JJ estimate_NN of_IN the_DT combined_VBN
          frequencies_NNS of_IN these_DT disorders_NNS in_IN adults_NNS in_IN central_JJ
          Alabama_NNP is_VBZ 0_CD ._. 0092_CD (_( 2_CD /_NN 217_CD )_) ._.
        
      
      
        Discussion_NNP
        The_DT present_JJ observations_NNS demonstrate_VBP that_IN CVID_NNP and_CC IgGSD_NNP
        in_IN Caucasian_NNP adults_NNS diagnosed_VBN in_IN routine_JJ medical_JJ care_NN
        delivery_NN are_VBP significantly_RB associated_VBN with_IN HLA_NNP haplotypes_NNS
        on_IN Ch_NNP 6_CD p_NN ._. More_JJR than_IN two-thirds_NNS of_IN the_DT present_JJ 195_CD index_NN
        patients_NNS who_WP were_VBD evaluable_JJ for_IN haplotyping_VBG inherited_VBN one_CD
        or_CC two_CD of_IN the_DT significantly_RB associated_VBN haplotypes_NNS
        A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD ,_, A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD ,_, A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD ,_, A_DT *_NN 03_CD -_: B_NNP *_NN 14_CD ,_, A_DT *_NN 31_CD -_: B_NNP *_NN 40_CD ,_, and_CC
        A_DT *_NN 32_CD -_: B_NNP *_NN 14_CD ._. This_DT indicates_VBZ that_IN a_DT susceptibility_NN locus_JJ
        (_( loci_NN )_) for_IN CVID_NNP and_CC IgGSD_NNP occurs_VBZ on_IN multiple_JJ haplotypes_NNS
        defined_VBN by_IN HLA-A_NNP and_CC -_: B_NNP typing_VBG ._. Further_RB ,_, this_DT implies_VBZ that_IN
        putative_JJ Ch_NNP 6_CD p_NN alleles_NNS associated_VBN with_IN CVID_NNP or_CC IgGSD_NNP
        susceptibility_NN occur_VB on_IN many_JJ HLA_NNP haplotypes_NNS that_WDT are_VBP common_JJ
        in_IN Caucasians_NNP in_IN central_JJ Alabama_NNP [_NN 10_CD ]_NN and_CC in_IN Caucasians_NNP
        from_IN a_DT large_JJ national_JJ bone_NN marrow_NN donor_NN program_NN [_NN 14_CD ]_NN ._.
        The_DT present_JJ observations_NNS also_RB confirm_VBP and_CC extend_VB the_DT
        reports_NNS of_IN association_NN of_IN HLA_NNP haplotype_NN A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD (_( or_CC an_DT
        extended_VBN haplotype_NN containing_VBG A_DT *_NN 01_CD and_CC B_NNP *_NN 08_CD )_) with_IN heritable_JJ
        forms_NNS of_IN immunoglobulin_NN deficiency_NN demonstrated_VBN in_IN
        family-based_JJ analyses_NNS [_NN 3_CD 6_CD 19_CD 20_CD 21_CD 22_CD ]_NN ._. It_PRP is_VBZ likely_JJ
        that_IN a_DT candidate_NN gene_NN (_( s_VBZ )_) for_IN CVID_NNP or_CC IgGSD_NNP exists_VBZ in_IN the_DT
        HLA_NNP class_NN II_NNP region_NN ,_, [_NN 6_CD 19_CD 20_CD 21_CD 22_CD 23_CD ]_NN ._. Because_IN the_DT
        class_NN II_NNP region_NN is_VBZ closer_JJR to_TO the_DT HLA-B_NNP locus_JJ than_IN to_TO the_DT
        HLA-A_NNP locus_JJ ,_, it_PRP is_VBZ plausible_JJ that_DT candidate_NN gene_NN (_( s_VBZ )_) for_IN
        CVID_NNP or_CC IgGSD_NNP in_IN the_DT class_NN II_NNP region_NN are_VBP in_IN greater_JJR linkage_NN
        disequilibrium_NN with_IN HLA-B_NNP than_IN HLA-A_NNP ._. This_DT is_VBZ consistent_JJ
        with_IN the_DT aggregate_JJ observations_NNS on_IN HLA-A_NNP and_CC -_: B_NNP typing_VBG in_IN
        the_DT present_JJ study_NN ._.
        The_DT present_JJ observations_NNS demonstrate_VBP that_IN the_DT
        frequencies_NNS of_IN HLA-A_NNP and_CC -_: B_NNP phenotypes_NNS and_CC haplotypes_NNS were_VBD
        not_RB significantly_RB different_JJ in_IN CVID_NNP and_CC IgGSD_NNP index_NN
        patients_NNS ,_, with_IN few_JJ exceptions_NNS ._. These_DT observations_NNS could_MD be_VB
        explained_VBN by_IN the_DT occurrence_NN of_IN an_DT HLA-linked_NNP allele_NN that_WDT is_VBZ
        necessary_JJ to_TO cause_VB either_CC CVID_NNP or_CC IgGSD_NNP ,_, but_CC is_VBZ
        insufficient_JJ to_TO induce_VB a_DT specific_JJ immunoglobulin_NN deficiency_NN
        phenotype_NN ._. Alternatively_RB ,_, the_DT variable_JJ immunoglobulin_NN
        deficiency_NN phenotypes_NNS presently_RB classified_VBN as_IN CVID_NNP and_CC
        IgGSD_NNP are_VBP best_JJS explained_VBN by_IN the_DT co-inheritance_JJ of_IN multiple_JJ
        alleles_NNS ,_, each_DT of_IN which_WDT has_VBZ an_DT independent_JJ effect_NN on_IN the_DT
        immunoglobulin_NN deficiency_NN phenotype_NN ._. Regardless_RB ,_, the_DT
        variability_NN we_PRP observed_VBD in_IN IgG_NNP ,_, IgA_NNP ,_, and_CC IgM_NNP phenotypes_NNS in_IN
        index_NN patients_NNS and_CC family_NN members_NNS is_VBZ best_JJS explained_VBN by_IN the_DT
        co-inheritance_JJ of_IN multiple_JJ allele_NN (_( s_VBZ )_) that_DT influence_NN the_DT
        immunoglobulin_NN phenotype_NN ._. This_DT is_VBZ consistent_JJ with_IN evidence_NN
        for_IN the_DT occurrence_NN on_IN Ch_NNP 6_CD p_NN of_IN multiple_JJ distinct_JJ
        susceptibility_NN genes_NNS for_IN patterns_NNS of_IN immunoglobulin_NN
        deficiency_NN ,_, some_DT recessive_JJ and_CC others_NNS dominant_JJ [_NN 20_CD ]_NN ._. For_IN
        example_NN ,_, at_IN least_JJS two_CD putative_JJ alleles_NNS associated_VBN with_IN
        heritable_JJ IgA_NNP deficiency_NN occur_VB on_IN Ch_NNP 6_CD p_NN ,_, and_CC each_DT is_VBZ
        associated_VBN with_IN a_DT different_JJ major_JJ histocompatibility_NN (_( MHC_NNP )_)
        region_NN haplotype_NN [_NN 22_CD 23_CD ]_NN ,_, whereas_IN a_DT putative_JJ
        susceptibility_NN locus_JJ on_IN chromosome_NN 18_CD is_VBZ not_RB a_DT major_JJ
        contributor_NN to_TO selective_JJ IgA_NNP deficiency_NN [_NN 24_CD ]_NN ._. Allele_NNP (_( s_VBZ )_)
        on_IN chromosomes_NNS other_JJ than_IN Ch_NNP 6_CD p_NN may_MD also_RB influence_VB the_DT
        phenotypic_JJ expression_NN of_IN CVID_NNP and_CC IgGSD_NNP in_IN adults_NNS ._. The_DT
        inheritance_NN of_IN certain_JJ polymorphisms_NNS of_IN the_DT mannose-binding_JJ
        lectin_NN gene_NN on_IN Ch_NNP 10_CD in_IN persons_NNS with_IN CVID_NNP are_VBP associated_VBN
        with_IN earlier_JJR age_NN of_IN onset_NN of_IN manifestations_NNS of_IN antibody_NN
        deficiency_NN and_CC with_IN increased_VBN risk_NN of_IN autoimmunity_NN [_NN 25_CD ]_NN ._.
        Altogether_RB ,_, these_DT observations_NNS are_VBP consistent_JJ with_IN the_DT
        hypothesis_NNS that_IN many_JJ common_JJ heritable_JJ antibody_NN deficiency_NN
        phenotypes_NNS collectively_RB diagnosed_VBN as_IN CVID_NNP or_CC IgGSD_NNP are_VBP the_DT
        result_NN of_IN the_DT inheritance_NN of_IN multiple_JJ disease-predisposing_JJ
        alleles_NNS on_IN Ch_NNP 6_CD p_NN and_CC possibly_RB other_JJ chromosomes_NNS ._.
        We_PRP have_VBP estimated_VBN that_IN the_DT prevalence_NN of_IN CVID_NNP and_CC IgGSD_NNP
        in_IN adults_NNS in_IN central_JJ Alabama_NNP is_VBZ 0_CD ._. 0092_CD ._. This_DT estimated_VBN
        prevalence_NN could_MD be_VB reasonably_RB attributed_VBN to_TO the_DT fact_NN that_IN
        many_JJ of_IN the_DT HLA_NNP haplotypes_NNS significantly_RB associated_VBN with_IN
        CVID_NNP and_CC IgGSD_NNP are_VBP also_RB common_JJ in_IN the_DT general_JJ population_NN ._.
        This_DT could_MD also_RB explain_VB a_DT )_) the_DT inheritance_NN of_IN two_CD
        significantly_RB associated_VBN HLA_NNP haplotypes_NNS in_IN many_JJ of_IN the_DT
        present_JJ index_NN cases_NNS ,_, including_VBG most_JJS of_IN the_DT index_NN patients_NNS
        who_WP were_VBD HLA-haploidentical_NNP with_IN at_IN least_JJS one_CD other_JJ index_NN
        patient_NN ;_: b_SYM )_) the_DT disparate_JJ immunoglobulin_NN deficiency_NN
        phenotypes_NNS of_IN multiple_JJ family_NN members_NNS who_WP inherited_VBD the_DT
        same_JJ HLA_NNP haplotype_NN ;_: and_CC c_SYM )_) the_DT occurrence_NN of_IN disparate_JJ
        haplotypes_NNS in_IN two_CD sisters_NNS who_WP had_VBD similar_JJ immunoglobulin_NN
        phenotypes_NNS ._.
        Some_DT of_IN the_DT haplotypes_NNS significantly_RB associated_VBN with_IN
        CVID_NNP and_CC IgGSD_NNP in_IN the_DT present_JJ study_NN also_RB occur_VB with_IN
        significantly_RB increased_VBN frequencies_NNS in_IN central_JJ Alabama_NNP
        Caucasian_NNP hemochromatosis_NNS probands_NNS with_IN homozygosity_NN for_IN 
        HFE_NNP C_NNP 282_CD Y_NNP on_IN Ch_NNP 6_CD p_NN [_NN 10_CD ]_NN ._. These_DT
        haplotypes_NNS are_VBP A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD and_CC A_DT *_NN 03_CD -_: B_NNP *_NN 14_CD [_NN [_NN 10_CD ]_NN ;_: present_JJ
        study_NN ]_NN ._. These_DT observations_NNS imply_VBP that_IN susceptibility_NN
        alleles_NNS for_IN CVID_NNP and_CC IgGSD_NNP occur_VBP on_IN haplotypes_NNS that_WDT
        sometimes_RB include_VBP the_DT 
        HFE_NNP C_NNP 282_CD Y_NNP allele_NN ._. In_IN addition_NN ,_, the_DT
        haplotypes_NNS A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD and_CC A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD significantly_RB associated_VBN
        with_IN CVID_NNP and_CC IgGSD_NNP in_IN the_DT present_JJ study_NN are_VBP common_JJ in_IN both_DT
        hemochromatosis_NNS probands_NNS homozygous_JJ for_IN 
        HFE_NNP C_NNP 282_CD Y_NNP and_CC control_NN subjects_NNS in_IN
        Alabama_NNP [_NN [_NN 10_CD ]_NN ;_: present_JJ study_NN ]_NN ._. Taken_VBN together_RB ,_, these_DT
        observations_NNS could_MD explain_VB the_DT occurrence_NN of_IN CVID_NNP or_CC IgGSD_NNP
        and_CC hemochromatosis_NNS due_JJ to_TO 
        HFE_NNP C_NNP 282_CD Y_NNP homozygosity_NN in_IN some_DT of_IN the_DT
        present_JJ index_NN patients_NNS [_NN 26_CD ]_NN and_CC account_NN for_IN the_DT
        occurrence_NN of_IN IgA_NNP deficiency_NN and_CC hemochromatosis_NNS in_IN
        different_JJ members_NNS of_IN the_DT same_JJ family_NN [_NN 27_CD ]_NN ._.
      
      
        Conclusions_NNP
        CVID_NNP and_CC IgGSD_NNP are_VBP significantly_RB associated_VBN with_IN the_DT HLA_NNP
        haplotypes_NNS A_DT *_NN 01_CD -_: B_NNP *_NN 08_CD ,_, A_DT *_NN 02_CD -_: B_NNP *_NN 44_CD ,_, A_DT *_NN 03_CD -_: B_NNP *_NN 07_CD ,_, A_DT *_NN 03_CD -_: B_NNP *_NN 14_CD ,_,
        A_DT *_NN 31_CD -_: B_NNP *_NN 40_CD ,_, and_CC A_DT *_NN 32_CD -_: B_NNP *_NN 14_CD ._. Many_JJ of_IN these_DT haplotypes_NNS are_VBP also_RB
        common_JJ in_IN the_DT Alabama_NNP Caucasian_NNP population_NN ._. Immunoglobulin_NNP
        phenotype_NN variability_NN demonstrated_VBN in_IN index_NN cases_NNS and_CC in_IN
        family_NN studies_NNS suggest_VBP that_IN there_EX are_VBP multiple_JJ gene_NN (_( s_VBZ )_) on_IN
        Ch_NNP 6_CD p_NN or_CC other_JJ chromosomes_NNS that_WDT modify_VB the_DT immunoglobulin_NN
        phenotypes_NNS of_IN CVID_NNP and_CC IgGSD_NNP ._. The_DT estimated_VBN prevalence_NN of_IN
        these_DT disorders_NNS in_IN central_JJ Alabama_NNP is_VBZ 0_CD ._. 0092_CD ._. The_DT estimated_VBN
        prevalence_NN of_IN CVID_NNP and_CC IgGSD_NNP in_IN central_JJ Alabama_NNP could_MD be_VB
        reasonably_RB attributed_VBN to_TO the_DT fact_NN that_IN many_JJ HLA_NNP haplotypes_NNS
        significantly_RB associated_VBN with_IN these_DT disorders_NNS are_VBP also_RB
        common_JJ in_IN the_DT general_JJ population_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( JCB_NNP )_) conceived_VBD the_DT study_NN ,_, and_CC contributed_VBD CVID_NNP
        and_CC IgGSD_NNP index_NN cases_NNS ,_, case_NN characterization_NN ,_, and_CC HLA_NNP
        typing_VBG ,_, tabulated_JJ index_NN case_NN HLA_NNP frequency_NN values_NNS ,_,
        performed_VBD statistical_JJ comparisons_NNS ,_, and_CC formulated_VBN the_DT
        manuscript_NN ._. Author_NN 2_CD (_( LFB_NNP )_) contributed_VBD CVID_NNP and_CC IgGSD_NNP index_NN
        cases_NNS ,_, case_NN characterization_NN ,_, and_CC HLA_NNP typing_VBG ._. Author_NN 3_CD
        (_( RTA_NNP )_) contributed_VBD control_NN subjects_NNS ,_, their_PRP$ characterization_NN ,_,
        and_CC control_NN HLA_NNP typing_VBG ,_, performed_VBD statistical_JJ comparisons_NNS ,_,
        and_CC edited_JJ the_DT manuscript_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD
        the_DT final_JJ manuscript_NN ._.
      
    
  
